Combination biologic therapy with lenalidomide and rituximab was active as initial therapy for patients with mantle-cell lymphoma, a new study published in The New England Journal of Medicine has shown.1

Lenalidomide, an immunomodulatory agent, and rituximab, an anti-CD20 antibody, have demonstrated activity in patients with recurrent mantle-cell lymphoma. Because initial therapy for mantle-cell lymphoma is not standardized and usually includes cytotoxic chemotherapy, researchers sought to evaluate the combination as first-line therapy.

For the single-group, multicenter, phase 2 study, researchers enrolled 38 treatment-naïve patients with mantle-cell lymphoma.

During the induction phase, participants received lenalidomide 20 mg daily on days 1 to 21 of every 28-day cycle for 28 cycles plus rituximab once weekly for the first 4 weeks and then once every other cycle until disease progression.

Lenalidomide could be dose-escalated to 25 mg daily after the first cycle if no dose-limiting toxicities occurred during the first cycle. Lenalidomide was then reduced to 15 mg daily during the maintenance phase

Results showed that at median follow-up of 30 months, the overall response rate among evaluable patients was 92% (95% CI, 78 – 98). The complete response rate was 64% (95% CI, 46 – 79).

Researchers found that the 2-year progression-free and overall survival was 85% (95% CI, 67 – 94) and 97% (95% CI, 79 – 99), respectively.

RELATED: Initial Findings Show Acceptable Safety With Ibrutinib for Asymptomatic, High-risk CLL

In regard to safety, the most common grade 3 or 4 adverse events were neutropenia, rash, thrombocytopenia, tumor flare, anemia, serum sickness, and fatigue.

The study also demonstrated an improvement in quality of life associated with response to treatment.

Reference

  1. Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015; 373(19):1835-1844.